Expand NNVC Menu
NNVC MENU

NNVC Latest Press Releases

-- April 7, 2026 --

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides ACCESS Newswire 8:30 AM

-- April 1, 2026 --

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides ACCESS Newswire 8:30 AM

-- March 11, 2026 --

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete ACCESS Newswire 8:30 AM

-- February 12, 2026 --

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides ACCESS Newswire 8:30 AM

-- February 10, 2026 --

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides ACCESS Newswire 8:30 AM

-- February 2, 2026 --

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres ACCESS Newswire 8:30 AM

-- January 23, 2026 --

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event ACCESS Newswire 2:51 PM

-- December 1, 2025 --

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles ACCESS Newswire 8:30 AM

-- November 17, 2025 --

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position ACCESS Newswire 8:30 AM

-- November 14, 2025 --

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 ACCESS Newswire 8:30 AM

-- November 12, 2025 --

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close ACCESS Newswire 5:01 PM
Market Data Delayed 15 Minutes